ClinicalTrials.gg
TerminatedNCT05589597AUDREYUpdated Oct 19, 2026Results posted

EO4010 in Previously Treated Metastatic Colorectal Carcinoma

A Phase 1/2 interventional study of EO4010 in Colorectal Cancer Metastatic, sponsored by Enterome. Terminated at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Enterome · Phase 1/2, Interventional, and Treatment

How we know · 4 judgments

Why this study was terminated
Sponsor decision to stop recruitment in context of overall EO4010 development goals. Stop of recruitment was not related to any safety concern, with the safety profile of EO4010 being benign
Updated Oct 19, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 583 studies in Colorectal Neoplasms with a site in France — 111 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.

Enrollment
408th of 464
25 · median 152
Started
2023
with 25 others
Phase 1/2
55 of 583
16 open now
Registered
464th of 583
by date

Among the 583 studies in Colorectal Neoplasms with a site in France, this one is the 408th largest by enrollment of the 464 interventional ones that give a count, is one of 26 that started in 2023, is one of 55 in phase 1/2, and was the 464th registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

111 of the 583 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 583 studies in Colorectal Neoplasms with a site in France, or all of them as a file.
02

Study summary

Open-label multicenter study

Read the detailed description

This is an open-label, multicenter, FIH, phase 1/2 trial to assess safety, tolerability, immunogenicity, and preliminary efficacy of the microbial-derived therapeutic vaccine EO4010 in combination with nivolumab and/or bevacizumab for treatment of patients with unresectable, previously treated, metastatic colorectal cancer

03

Conditions studied

  • Colorectal Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provided written
  2. Histological confirmation of advanced non-resectable colorectal adenocarcinoma
  3. Patients with colorectal cancer who have been previously treated with, or are not considered candidates for
  4. Progression during or within 3 months following the latest administration of standard therapies
  5. Age ≥ 18 years old
  6. Human leukocyte antigen (HLA)-A2 positive
  7. performance status 0 or 1
  8. according to criteria (RECIST)
  9. Patients with a of at least 3 months
  10. Female patients of must have a negative serum pregnancy test
  11. Patients following recommendations for
  12. Patients willing and able to comply with the study procedures

Exclusion criteria

Exclusion Criteria:

  1. Patients treated with dexamethasone > 2 mg/day or equivalent within 14 days before randomization, unless required to treat an adverse event
  2. Patients treated with radiotherapy within 12 weeks, and cytotoxic chemotherapy therapy within 28 days
  3. Patients with persistent Grade ≥ 2 toxicities (according to v5.0). Toxicities must be resolved for at least 2 weeks to Grade 1 or less
  4. Patients who have received any prior treatment with compounds targeting PD1, PDL1, , or similar compounds
  5. Patients who have previously received trifluridine/tipiracil (TAS-102) or regorafenib
  6. Patients with prior exposure to EO2401, EO2040, or EO4010, i.e. therapeutic vaccine compounds including all or some components of EO4010
  7. Patients with the following abnormal laboratory values:

    1. Lymphocyte count decreased, grade 2 (lymphocytes \<800 - 500/mm3; \<0.8 - 0.5 x 109/L), or worse grade
    2. \< 10 g/dL (6.2 mmol/L); transfusion is acceptable to reach the value
    3. decrease (\<1.5 x109/L)
    4. count decrease (\< 75 ×109/L)
    5. Total > 1.5 ×
    6. (ALT) > 3 ×ULN; if disease to the liver > 5 xULN
    7. Aspartate aminotransferase (AST) > 3 ×ULN; if disease metastatic to the liver > 5 xULN
    8. Serum creatinine increase (> 1.5 ×ULN)
    9. Abnormal thyroid function per local laboratory levels
  8. Other or prior malignancy with a disease-free interval of less than 3 years prior to ICF signing; except those treated with surgical intervention and an expected low likelihood of recurrence
  9. Patients with active infection, cardiac disease, significant medical or psychiatric disease/condition
  10. Patients with suspected or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g., Guillain-Barré syndrome)
  11. Patients with a history of solid organ transplantation or hematopoietic stem cell transplantation
  12. Patients with a history or known presence of tuberculosis
  13. Pregnant and breastfeeding patients
  14. Patients with a history or presence of (HIV) and/or active virus (HBV)/ virus (HCV)
  15. Uncontrolled central nervous system (CNS) metastasis
  16. Patients who have received live or attenuated vaccine therapy used for prevention of infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the first dose of study drug
  17. Patients with a history of to any , or active substance, present in the pharmaceutical forms of applicable study treatments
  18. Patients under treatment with immunostimulatory or medications
  19. Patients who have received treatment with any other agent, or participation in another clinical trial
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Cohort 1

    E04010 Monotherapy

    Drug: EO4010

  • Experimental
    Cohort 2

    E04010 in combination with nivolumab

    Drug: EO4010

  • Experimental
    Cohort 3

    E04010 in combination with nivolumab and/or bevacizumab

    Drug: EO4010

Interventions

  • DrugEO4010

    Sequential assignment

    Also known as: Nivolumab, Bevacizumab

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of EO4010 in Combination With Nivolumab and/or Bevacizumab

    Incidences of treatment-emergent Serious Adverse Events (SAEs) using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

    Time frame: 24 months

Secondary outcomes

  1. Percentage of Patients With Shown Immunogenicity Againts EO4010 (All Peptides)

    Immunogenicity response of EO4010 (all peptides) for the three tests together: IFN-gamma ElISpot \[IVS\], IFN-gamma ElISpot \[NS\], multimer staining \[NS\]. A patient is defined as positive if the result of one of the three tests (IFN-gamma ElISpot \[IVS\], IFN-gamma ElISpot \[NS\], multimer staining \[NS\]) shows a positive response

    Time frame: Week 5 after first dose of EO4010

  2. Overall Response Rate

    Defined as the percentage of patients who have a partial or complete response following Response Evaluation Criteria in Solid Tumors criteria

    Time frame: 24 months

  3. Disease Control Rate

    Defined as the percentage of patients who have achieved complete response, partial response or stable disease following Response Evaluation Criteria in Solid Tumors criteria

    Time frame: 24 months

  4. Time to Response

    Defined as the time interval from first study treatment administration to partial or complete response following Response Evaluation Criteria in Solid Tumors criteria

    Time frame: 24 months

  5. Duration of Response

    Defined as the time interval from first study treatment administration to disease progression or death in patients who achieve complete or partial response following Response Evaluation Criteria in Solid Tumors criteria

    Time frame: 24 months

  6. Progression Free Survival

    Defined as the time interval from the date of first study treatment administration to the date of progression following Response Evaluation Criteria in Solid Tumors criteria

    Time frame: 24 months

  7. Overall Survival to the Date of Death Due to Any Cause. Patients Alive Will be Censored at the Date of the Last Documented Follow-up

    Defined as the time interval from the date of first study treatment administration to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up

    Time frame: 24 months

07

Results

Posted Oct 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1aCohort 2Cohort 3aCohorts 1b-1c-1d
Started31750
Completed31750
Not completed0000

Outcome measures

PrimarySafety and Tolerability of EO4010 in Combination With Nivolumab and/or Bevacizumab

Incidences of treatment-emergent Serious Adverse Events (SAEs) using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.

Time frame:
24 months
Reported as:
Count of participants · Participants
Safety and Tolerability of EO4010 in Combination With Nivolumab and/or Bevacizumab
ParticipantsOverall (All Cohorts)Cohort 1a (Overall)Cohort 1a (Monotherapy)Cohort 1a (Combo)Cohorts 1b-1c-1dCohort 2Cohort 3a
Safety and Tolerability of EO4010 in Combination With Nivolumab and/or Bevacizumab6000060
SecondaryPercentage of Patients With Shown Immunogenicity Againts EO4010 (All Peptides)

Immunogenicity response of EO4010 (all peptides) for the three tests together: IFN-gamma ElISpot \[IVS\], IFN-gamma ElISpot \[NS\], multimer staining \[NS\]. A patient is defined as positive if the result of one of the three tests (IFN-gamma ElISpot \[IVS\], IFN-gamma ElISpot \[NS\], multimer staining \[NS\]) shows a positive response

Time frame:
Week 5 after first dose of EO4010
Reported as:
Count of participants · Participants
Percentage of Patients With Shown Immunogenicity Againts EO4010 (All Peptides)
ParticipantsOverall (All Cohorts)Cohort 1a (Overall)Cohorts 1b-1c-1dCohort 2Cohort 3a
Percentage of Patients With Shown Immunogenicity Againts EO4010 (All Peptides)1720105
SecondaryOverall Response Rate

Defined as the percentage of patients who have a partial or complete response following Response Evaluation Criteria in Solid Tumors criteria

Time frame:
24 months
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsOverall (All Cohorts)Cohort 1a (Overall)Cohorts 1b-1c-1dCohort 2Cohort 3a
Overall Response Rate10010
SecondaryDisease Control Rate

Defined as the percentage of patients who have achieved complete response, partial response or stable disease following Response Evaluation Criteria in Solid Tumors criteria

Time frame:
24 months
Reported as:
Count of participants · Participants
Disease Control Rate
ParticipantsOverall (All Cohorts)Cohort 1a (Overall)Cohorts 1b-1c-1dCohort 2Cohort 3a
Disease Control Rate60033
SecondaryTime to Response

Defined as the time interval from first study treatment administration to partial or complete response following Response Evaluation Criteria in Solid Tumors criteria

Time frame:
24 months
Reported as:
Median · months
Time to Response
monthsOverall (All Cohorts)Cohort 1a (Overall)Cohorts 1b-1c-1dCohort 2Cohort 3a
Time to Response10.5 (10.5 to 10.5)——10.5 (10.5 to 10.5)—
SecondaryDuration of Response

Defined as the time interval from first study treatment administration to disease progression or death in patients who achieve complete or partial response following Response Evaluation Criteria in Solid Tumors criteria

Time frame:
24 months
Reported as:
Median · months
Duration of Response
monthsOverall (All Cohorts)Cohort 1a (Overall)Cohorts 1b-1c-1dCohort 2Cohort 3a
Duration of Response8.7 (NA to NA)——8.7 (NA to NA)—
SecondaryProgression Free Survival

Defined as the time interval from the date of first study treatment administration to the date of progression following Response Evaluation Criteria in Solid Tumors criteria

Time frame:
24 months
Reported as:
Median · months
Progression Free Survival
monthsOverall (All Cohorts)Cohort 1a (Overall)Cohorts 1b-1c-1dCohort 2Cohort 3a
Progression Free Survival1.9 (1.8 to 2.2)1.8 (1.8 to NA)—1.8 (1.8 to 2.2)2.4 (1.8 to NA)
SecondaryOverall Survival to the Date of Death Due to Any Cause. Patients Alive Will be Censored at the Date of the Last Documented Follow-up

Defined as the time interval from the date of first study treatment administration to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up

Time frame:
24 months
Reported as:
Median · months
Overall Survival to the Date of Death Due to Any Cause. Patients Alive Will be Censored at the Date of the Last Documented Follow-up
monthsOverall (All Cohorts)Cohort 1a (Overall)Cohorts 1b-1c-1dCohort 2Cohort 3a
Overall Survival to the Date of Death Due to Any Cause. Patients Alive Will be Censored at the Date of the Last Documented Follow-up11.4 (9.7 to NA)NA (10.1 to NA)—11.2 (4.7 to NA)NA (9.7 to NA)

Adverse events

Collected over 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall (All Cohorts)15/25 (60%)6/25 (24%)25/25 (100%)
Cohort 1a (Overall)1/3 (33.3%)0/3 (0%)3/3 (100%)
Cohort 1a (Monotherapy)0/3 (0%)0/3 (0%)3/3 (100%)
Cohort 1a (Combo)1/3 (33.3%)0/3 (0%)3/3 (100%)
Cohorts 1b-1c-1d———
Cohort 212/17 (70.6%)6/17 (35.3%)17/17 (100%)
Cohort 3a2/5 (40%)0/5 (0%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventOverall (All Cohorts)Cohort 1a (Overall)Cohort 1a (Monotherapy)Cohort 1a (Combo)Cohorts 1b-1c-1dCohort 2Cohort 3a
PyelonephritisInfections and infestations2/250/30/30/3—2/170/5
Acute myocardial infarctionCardiac disorders1/250/30/30/3—1/170/5
Gastrointestinal obstructionGastrointestinal disorders1/250/30/30/3—1/170/5
Respiratory tract infectionInfections and infestations1/250/30/30/3—1/170/5
Infusion related reactionInjury, poisoning and procedural complications1/250/30/30/3—1/170/5
Acute kidney injuryRenal and urinary disorders1/250/30/30/3—1/170/5
Most frequent other events
Showing 10 of 49
Most frequent other events
EventOverall (All Cohorts)Cohort 1a (Overall)Cohort 1a (Monotherapy)Cohort 1a (Combo)Cohorts 1b-1c-1dCohort 2Cohort 3a
Injection site reactionGeneral disorders21/253/33/30/3—14/174/5
AstheniaGeneral disorders8/251/30/31/3—3/174/5
DiarrhoeaGastrointestinal disorders5/250/30/30/3—3/172/5
AnaemiaBlood and lymphatic system disorders5/251/30/31/3—4/170/5
LymphadenopathyBlood and lymphatic system disorders1/251/30/31/3—0/170/5
HyperthyroidismEndocrine disorders2/251/30/31/3—1/170/5
Tooth abscessInfections and infestations1/251/30/31/3—0/170/5
Wrong product administeredInjury, poisoning and procedural complications1/251/30/31/3—0/170/5
PolyarthritisMusculoskeletal and connective tissue disorders1/251/30/31/3—0/170/5
NeuralgiaNervous system disorders1/251/30/31/3—0/170/5

Baseline characteristics

The IDMC recommended to open recruitment of Cohort 2 utilizing the same dose level as in the safety lead-in, (300μg of each peptide, i.e. 1 mL of EO4010 in adjuvant) for Cohort 2. Therefore, Cohorts 1 b-c-d were not opened as per sponsor decision.

Age, Continuous
Age, Continuous(years)Cohort 1aCohort 2Cohort 3aCohorts 1b-c-dTotal
Median55 (45 to 56)61 (52 to 71)42 (40 to 67)—57 (50 to 67)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1aCohort 2Cohort 3aCohorts 1b-c-dTotal
Female293—14
Male182—11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1aCohort 2Cohort 3aCohorts 1b-c-dTotal
Hispanic or Latino030—3
Not Hispanic or Latino3145—22
Unknown or Not Reported000—0
Region of Enrollment
Region of Enrollment(participants)Cohort 1aCohort 2Cohort 3aCohorts 1b-c-dTotal
United States020—2
France3102—15
Spain053—8
08

Study locations

6 sites
  • MD Anderson
    Houston, Texas 77030, United States
  • Hôpital Jean Minjoz
    Besançon, 25030, France
  • ICM Val d'Aurelle
    Montpellier, 34298, France
  • Saint Antoine hospital
    Paris, 75012, France
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Llavero-Hospital Clínico Universitario
    Valencia, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in May 2025, 23 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 21, 2022
StartActual
Jun 1, 2023
Primary completionActual
May 30, 2025
CompletionActual
May 30, 2025
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedSafety and tolerabilityTolerability of EO4010 in combination with nivolumabCombination With Nivolumab and/or bevacizumabBevacizumabTime frame: 12months → 24 months
Oct 19, 2026
Documents
Secondary outcomes
7 edited
What changed in the outcomes
  • EditedPercentage of patients with shown immunogenicityPatients With Shown Immunogenicity Againts EO4010 (All Peptides)Time frame: 12 months → Week 5 after first dose of EO4010
  • EditedOverall response rateResponse RateTime frame: 12 months → 24 months
  • EditedDisease control rateControl RateTime frame: 12 months → 24 months
  • EditedTime to responseResponseTime frame: 12 months → 24 months
  • EditedDuration of responseResponseTime frame: 12 months → 24 months
  • EditedProgression free survivalFree SurvivalTime frame: 4months → 24 months
  • EditedOverall survivalSurvival to the dateDate of death dueDeath Due to any causeAny Cause. Patients alive willAlive Will be censoredCensored at the dateDate of the last documented followLast Documented Follow-upTime frame: 12 months → 24 months
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedSafety and tolerabilityTolerability of EO4010 in combination with nivolumabCombination With Nivolumab and/or bevacizumabBevacizumabTime frame: 12months → 24 months
    Secondary outcomes 7 edited
    What changed in the outcomes
    • EditedPercentage of patients with shown immunogenicityPatients With Shown Immunogenicity Againts EO4010 (All Peptides)Time frame: 12 months → Week 5 after first dose of EO4010
    • EditedOverall response rateResponse RateTime frame: 12 months → 24 months
    • EditedDisease control rateControl RateTime frame: 12 months → 24 months
    • EditedTime to responseResponseTime frame: 12 months → 24 months
    • EditedDuration of responseResponseTime frame: 12 months → 24 months
    • EditedProgression free survivalFree SurvivalTime frame: 4months → 24 months
    • EditedOverall survivalSurvival to the dateDate of death dueDeath Due to any causeAny Cause. Patients alive willAlive Will be censoredCensored at the dateDate of the last documented followLast Documented Follow-upTime frame: 12 months → 24 months
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05589597
Lead sponsor
Enterome
Responsible party
Sponsor
First posted
Oct 21, 2022
Start date
Jun 1, 2023
Primary completion
May 30, 2025
Completion
May 30, 2025
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Study contacts

Jan Fagerberg
study director · Enterome

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion